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Abstract:
Background: Chronic breathlessness is a disabling syndrome that 
profoundly impacts patients’ and caregivers’ lives. Driving is important 
for most people, including those with advanced disease. Regular, low 
dose, sustained-release morphine safely reduces breathlessness, but 
little is known about its impact on driving. 
Aim: To understand patients’ and caregivers’ (i) perspectives and 
experiences of driving with chronic breathlessness; and (ii) perceived 
impact of regular, low-dose, sustained-release morphine on driving. 
Design: A qualitative study embedded in a pragmatic, phase III, 
randomised, placebo-controlled trial (RCT) of low-dose, sustained-
release morphine (≤32mg/24 hours) for chronic breathlessness. Semi-
structured interviews were conducted immediately after participants 
withdrew or completed the RCT. Informed by grounded theory, a 
constant comparative approach to analysis was adopted. 
Setting/participants: Participants were recruited from an outpatients 
palliative-care service in Adelaide, Australia. Participants included: 
patients (n=13) with severe breathlessness associated with chronic 
obstructive pulmonary disease; and their caregivers (n=9). 
Results: Participants were interviewed at home. Eleven received 




breathlessness’ impact on driving; and iii) driving while taking regular, 
low-dose, sustained-release morphine.   
Conclusions: Driving contributed to a sense of identity and 
independence. Being able to drive increased the physical and social 
space available to patients and caregivers, their social engagement and 
well-being. Patients reported breathlessness at rest may impair driving 
skills, while the introduction of sustained-release morphine seemed to 
have no self-reported impact on driving. Investigating this last 
perception objectively, especially in terms of safety, is the subject of 
ongoing work. 
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Background: Chronic breathlessness is a disabling syndrome that profoundly impacts 
patients’ and caregivers’ lives. Driving is important for most people, including those with 
advanced disease. Regular, low dose, sustained-release morphine safely reduces 
breathlessness, but little is known about its impact on driving. 
Aim: To understand patients’ and caregivers’ (i) perspectives and experiences of driving with 
chronic breathlessness; and (ii) perceived impact of regular, low-dose, sustained-release 
morphine on driving.
Design: A qualitative study embedded in a pragmatic, phase III, randomised, placebo-
controlled trial (RCT) of low-dose, sustained-release morphine (≤32mg/24 hours) for chronic 
breathlessness. Semi-structured interviews were conducted immediately after participants 
withdrew or completed the RCT. Informed by grounded theory, a constant comparative 
approach to analysis was adopted. 
Setting/participants: Participants were recruited from an outpatients palliative-care service 
in Adelaide, Australia. Participants included: patients (n=13) with severe breathlessness 
associated with chronic obstructive pulmonary disease; and their caregivers (n=9).
Results: Participants were interviewed at home. Eleven received morphine 8-32mg. Three 
themes emerged: i) independence; ii) breathlessness’ impact on driving; and iii) driving while 
taking regular, low-dose, sustained-release morphine.  
Conclusions: Driving contributed to a sense of identity and independence. Being able to 
drive increased the physical and social space available to patients and caregivers, their 
social engagement and well-being. Patients reported breathlessness at rest may impair 
driving skills, while the introduction of sustained-release morphine seemed to have no self-
reported impact on driving. Investigating this last perception objectively, especially in terms 
of safety, is the subject of ongoing work. 
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What is already known about the topic?
 Chronic breathlessness is a debilitating syndrome, which can be ameliorated by 
small doses of regular, low-dose, sustained-release morphine in some people.
 Driving is important for most adults, including the ones with life-limiting illnesses 
associated with chronic breathlessness.
 Despite growing concerns about the impact of opioids on driving ability, there are no 
studies investigating people’s experiences of driving with chronic breathlessness 
before or after initiating treatment with regular, low-dose, sustained-release 
morphine.  
What this paper adds?
 Being able to drive is important for people with chronic breathlessness and their 
caregivers because it provides them with a continuing sense of self-worth, 
independence, pleasure and widening life space.
 Episodes of intense breathlessness can impact on patients’ perceived ability to drive, 
which is not easily perceived by caregivers. 
 Although people have fears surrounding driving while taking morphine, regular, low-
dose sustained-release morphine does not seem to impact on patients’ self-
perceived driving ability.
Implications for practice, theory and policy
 In clinical practice, it is important to enquire about peoples’ perceived ability to drive 
with chronic breathlessness and the medications that they are prescribed.
 Clinical research should focus on investigating whether oral, low-dose sustained-
release morphine impacts on patients’ driving ability, particularly during initiating 
therapy and any subsequent dose increases. 
 Understanding the impact of low-dose, sustained release morphine on people’s 
driving ability is essential to inform guideline development about who is able to drive 
safely and who is not. 


































































Chronic breathlessness persists and is disabling despite optimal treatment of the underlying 
disease(s). [1] Chronic breathlessness affects almost 10% of adults and 17% of those ≥65 
years. [2] Patients with chronic obstructive pulmonary disease (COPD) are particularly 
affected, with >90% reporting breathlessness at some stage. [3] Chronic breathlessness is 
physically and psychologically debilitating, [4] leading to increasing dependence, social 
isolation, and worse health-related and mortality outcomes. [5, 6] Loss of independence is 
also profoundly distressing for caregivers, who struggle seeing their loved ones’ decline. [7, 
8] 
Driving provides a sense of freedom, independence, identity and hope. [9] Not driving 
worsens social isolation and is associated with worse health-related outcomes. [10, 11] One 
quarter of people with life-limiting illnesses continue driving. [12] Although there is ample 
evidence that chronic breathlessness severely restricts people’s everyday lives, the effect of 
chronic breathlessness on people’s driving ability has not been explored. 
Regular, low-dose (≤30mg/day), [13] sustained-release morphine safely reduces chronic 
breathlessness in people with COPD. [14, 15] Recently, low-dose, sustained-release 
morphine has been approved by regulatory bodies in Australia for the treatment of chronic 
breathlessness. [16] This is the first world approval of any medication for the symptomatic 
reduction of chronic breathlessness, likely increasing prescriptions for this indication. 
Simultaneously, there are concerns about safe driving while taking psychoactive substances, 
including prescribed opioids. [17] While high dose opioids can impair driving, it is unknown 
whether regular, low dose, sustained-release morphine impacts on patients’ ability to drive, 
particularly when initiating therapy and up-titration. [18] 
This aim of this qualitative study was to elicit patients’ and caregivers’ perceptions about 

































































driving with chronic breathlessness and to understand their perceptions about driving as 
regular, low dose, sustained release morphine was introduced. 
METHODS
Design
A qualitative study embedded in a pragmatic, phase III, randomised, placebo-controlled trial 
(RCT) evaluating the effectiveness of sustained-release morphine for people with chronic 
breathlessness and COPD (BEAMS trial). [19] The RCT had a parallel-arm, dose increment 
design. Participants were randomised to placebo, 8mg or 16mg of once-daily sustained-
release morphine for one week, with possible additional blinded up-titrations, of 8 or 16mg in 
weeks 2 and 3. Maximum daily doses of morphine by the end of the randomisation period 
ranged from 0mg (placebo) to 32mg (0, 8, 16, 24 or 32mg), with chances of being on 
placebo after randomisation being 1:12. The trial primary outcome measure was change in 
intensity of “worst breathlessness” in the previous 24 hours, measured with a 0-10 numerical 
rating scale after one week of therapy. The pragmatic design ensured that participants 
included in the RCT were a close reflection of the population of interest. [20,21] 
Setting and Participants
Participants were recruited from the metropolitan region serviced be the Southern Adelaide 
Palliative Services, Australia. Participants included: patients who had ceased their 
participation in the BEAMS trial [19] either by completion or withdrawal; and ‘the person 
closest to the patient’ (‘caregiver’), if present. [22] This sampling provided a broad range of 
perspectives. All patients had COPD and chronic breathlessness; a modified Medical 
Research Council (mMRC) breathlessness score of 3 or 4 corresponding to “stops for breath 
after walking about 100 meters or stops after a few minutes walking on the level” and “too 
breathlessness to leave the house or breathlessness when dressing or undressing”, 

































































respectively. [23,24] Participants were active drivers or people who had recently stopped 
driving and were still able to recall their experience of driving with severe chronic 
breathlessness. The latter group’s perceptions contributed to expand the understanding of 
the experience of driving with this disabling syndrome, but were not questioned about their 
experiences of driving after initiating sustained-release morphine.
Research Team
The interviewer (D.F.) has a medical background and was a full-time doctoral student with 
training in qualitative research. J.B. is Senior Clinical Lecturer and Honorary Consultant in 
Palliative Medicine with a medical and research background. A.H. is a university researcher 
with background in data collection and people-centred research. S.K. is a university 
researcher with a linguistics background. J.P. is a senior researcher with a background in 
palliative care nursing and qualitative research. D.C. is a researcher with expertise in chronic 
breathlessness.
Recruitment
Using convenience sampling, the trial nurses approached potential participants by 
telephone. If interested, they were then phoned by the interviewer (D.F.), with whom they 
had no previous contact. The interviewer explained the study’s objectives and scheduled a 
face-to-face meeting with potential participants to answer questions and obtain written 
consent. 
Data collection
Face-to-face, semi-structured interviews were conducted separately with patients and their 
caregivers at a location of their choice (July 2017- November 2018), providing participants 
with safe and private settings to express freely any concerns or emotions. [25,26] Interviews 
evaluated the overall impact of chronic breathlessness in people’s daily lives and perceived 

































































changes after initiating study drug. [19] Given the lack of evidence examining experiences of 
driving in people with chronic breathlessness, the interviews included three questions about 
driving, analysed in a separate sub-study (Box 1). 
Participants’ responses were recorded and transcribed verbatim (D.F.). Field notes were 
collected and the researcher kept a reflexive journal with impressions about each participant-
researcher interaction. Interview transcripts were not reviewed by participants to minimise 
burden on people already debilitated due to chronic breathlessness, given minimal 
advantages from doing this. [27] Potential misinterpretations were minimised by having a 
second researcher (A.H.) listen to interviews’ recordings, checking transcriptions for 
accuracy. Participants were only contacted again if there were disagreements between 
these researchers. Data were collected until saturation (i.e. no new concepts were 
emerging), as agreed between all researchers. 
Data Analysis
NVivo (V 11.4.0 for Mac) was used. The analysis was driven by the principles of grounded 
theory, using a constant comparative approach. [28,29,30] Given the lack of qualitative 
studies exploring people’s experiences of driving with chronic breathlessness, an inductive 
approach to analysis was adopted. [31] The constant comparative approach helped identify 
new concepts emerging from the data that could be explored in subsequent interviews. [30] 
Two researchers independently conducted open coding (D.F., A.H.) of all transcripts, which 
were grouped into themes (D.F.); each theme was illustrated with several quotes to confirm 
coding validity (D.F., J.B., S.K., J.P.). Patients’ and caregivers’ viewpoints were then 
compared and contrasted. 
Ethical considerations
The BEAMS trial was approved by relevant Human Research Ethics Committees 
(15/12/16/3.06) and was registered (NCT02720822). All participants provided written 
informed consent. 

































































The COREQ framework is used to report this study. [32]
RESULTS
Fifteen patients and 11 matched caregivers were invited to this study: two patients declined 
(so their caregivers were excluded); 13 patients and 9 caregivers were interviewed. 
Interviews took 20-55 minutes. Patients had a median age of 76 years (interquartile range 
[IQR] 68-78), nine of whom were men, living with their partners. All were still mobile outside 
their homes, but were severely restricted in their daily activities due to breathlessness (Table 
1).
Eight of 13 patients were regularly driving and one drove occasionally. Only two of nine men 
had stopped driving, while two of four women had stopped driving. The four participants who 
had stopped driving had all driven regularly until recently (Table 2). Eleven patients took 
sustained-release morphine during the study (Table 3): 8mg (n=4), 16mg (n=3), 24mg (n=3) 
and 32mg (n=1). 
Three major themes described the experience of driving for patients with chronic 
breathlessness and their caregivers: 1) independence, 2) breathlessness’ impact on driving, 
3) driving while taking regular low-dose sustained-release morphine (Table 4).
Theme 1 - Independence
Being able to drive helped patients keep their sense of self and feeling useful. This was 
more noticeable in patients experiencing severe functional limitations due to breathlessness. 
“Well, I suppose it’s something that I don’t do every day (driving) and you know, and I 
am doing something! Maybe that’s the reason why… Well I’ve always enjoyed driving 
actually but more so now, more so now, yeah… Probably because it’s something 
different in my life now, you know? I can do something! Whereas usually, I am just 
sitting.” [Patient 8]

































































Most patients reported that driving was one of the few activities that brought them a sense of 
joy and pleasure. Even those patients not required to drive (i.e. because their caregiver 
drove), still felt the need to drive at times for pure enjoyment.
“We have got the van and I drive the van. I love getting out in the country and 
driving.” [Patient 12]
For caregivers, seeing their partners enjoy themselves was particularly importantly. They 
acknowledged the role of driving in widening the physical space available to both the 
patients and themselves, a space that had been severely reduced by breathlessness in most 
cases. 
“Well, driving is important… There are certain things… When we go on holiday 
because he is not bothered about walking out on the streets, you know? (…) But we 
went to Barossa Valley last week, and I don’t know if you have been there, but we 
went to Mengler’s Hill to the look out. He got up there, well we drove up there of 
course, we got out of the car and we walked down a little bit to the picnic area there 
and he stayed there while I walked around and looked at it because walking down 
and up and down… [meaning it was tiresome for him]. So things like that you know?” 
[Caregiver 11]
For some patients, driving was their most important activity. One patient without a caregiver 
explained that driving was key to maintaining relationships and roles, whilst also providing a 
sense of purpose:
“I get my adult daughter every Saturday for a while, she is profoundly autistic, she 
just had her 26th birthday yesterday and it is very important to her. So I have got to 
drive to go get her, drive to bring her back. So it’s a very important thing, making sure 

































































I can still drive. (…) And that’s the main reason, apart from that, it is just to get to the 
shop and the doctor which are a kilometer away. That’s the only big one.” [Patient 3]
Another patient explained that driving was the only out-of-home activity he was still able to 
do independently and that losing it would be extremely disturbing.
“Well, I think the most important thing to be able to do at the moment is to be able to 
drive because physically there is nothing I can do, I can’t do anything”. [Patient 8]
 
Overall, people who were still driving expressed fear about not being able to drive in the 
future. Driving was seen as an important marker of independence and there was fear over 
any loss and its consequences. 
“I couldn’t give up driving, I couldn’t do that [disturbed facial expression]. I think it’s 
your independence, you know? And once that is taken away you’re reliant on 
somebody else…” [Patient 9]
For the four patients who had stopped driving, only one (male) reported that driving was 
important to maintain his independence. The other three patients (one male, two females) 
reported driving was not overly important because their caregivers could drive when needed. 
 
“It gives me a lot more freedom to have the car. I don’t do things that I would 
normally do… If I had the car and I felt like KFC for lunch, I can go and get it 
(laughing)… or if I wanted to go out for dinner with someone, I could just go and do it. 
Whereas now, for me to walk to the bus stop to get a bus somewhere, it’s just too 
hard…” [Patient 10]

































































“I don’t miss driving. B. (husband) does everything. We are together all the time 
anyway.” [Patient 1]
Breathlessness’ impact on driving
In general, patients and caregivers considered that breathlessness did not reduce patients’ 
driving skills because it did not require over-exertion. 
“Normally, I am fine. I don’t get tired driving.” [Patient 7]
Some patients reported they had situations in which they felt breathlessness at rest. When 
present, they felt their driving ability was affected. Strategies to overcome this limitation 
included not driving at all or using oxygen while driving. Interestingly, the use of oxygen in 
the car raised some concerns about its safety and legality.
“There were a couple of times in which I have been buggered a bit. I haven’t had the 
oxygen the night before, so I will put the oxygen on the car and I will have the oxygen 
running while I am driving. Whether that’s legal or not I don’t know.” [Patient 11]
One patient experiencing breathlessness at rest explained that breathlessness impacted on 
his concentration and hence ability to drive. When he drove, he felt anxious and concerned 
about his and other people’s safety.    
“For me it is not so much driving, but the concentration level about what is going on 
around. Stuff I used to take for granted, so I automatically did it before. Now, I have 
to make sure I do it. And it depends on the concentration because if it is 
concentrating on something that could end in a disaster, is a bit different to 
concentrating on something that might just a non-event anyway.” [Patient 13]

































































Overall, caregivers’ views matched patients’ views. Most caregivers confirmed that patients 
drove safely despite their breathlessness. For the only patient who stated that driving was 
stressful (previous quote, patient 13), the caregiver thought he could still drive safely. 
“Yes, usually when we go stay with our son at Wallaroo, he drives there. So he can. 
And he is quite good, I think. I don’t notice any diminishing of his driving skills. I feel 
quite relaxed when he is driving.” [Caregiver 13]
Driving while taking regular, low-dose sustained-release morphine
Participants’ views on driving were quite uniform, irrespectively of the drug (i.e. morphine or 
placebo) and dose. Most patients and caregivers perceived that the study drug did not have 
any perceived adverse impact on patients’ ability to drive, irrespectively of the study drug/dose. 
“No, no problems (to drive while taking the study drug).” [Patient 7 - maximum 
morphine dose 32mg]
 “No, no, not at all. I don’t think driving was affected (by morphine)”. [Caregiver 2 – 
maximum morphine dose 16mg]
Despite not perceiving any impact on driving with the study drug, a small number of 
participants were still concerned about the potential effects of morphine on driving. Most 
believed that the trial dose (up to 32mg sustained-release morphine a day) could impair 
driving. One caregiver did not want the patient to continue with morphine because she 
believed morphine could lead to driving cessation. One patient took action to minimise any 
negative impact of morphine on his driving skills. 

































































“I was concerned about… If he does take it, I think he wouldn’t be able to drive (…)  
and I don’t really want him to go on that because he loves driving and I think if he 
took it, that would be the end. I want him to be around for a few more years yet.” 
[Caregiver 8 – maximum morphine dose 8mg]
 “I have a friend coming here and he will sit with me (while I drive) and tells me what is 
going on with the driving. (…) I know they say if I am taking a quite powerful opioid 
drug that driving while under the immediate influence is probably not that smart. I would 




This is the first study reporting patients’ and caregivers’ perspectives and experiences of 
driving with chronic breathlessness. Additionally, the study was set in a study to compare 
before-and-after taking regular, low dose, oral sustained-release morphine. Findings suggest 
that driving is crucial in helping patients with chronic breathlessness keep a sense of identity, 
purpose, independence and connection to the outside world, while also being a source of joy 
and comfort for both patients and caregivers. According to patients, breathlessness at rest 
can reduce their driving skills but the study drug (i.e. morphine/placebo) had no perceived 
impact on their ability to drive.
Similar to healthy individuals, owning and driving a private vehicle is perceived as an 
amenity offering people freedom of movement. [33] However, participants’ reflections 
highlight that the ability to drive is particularly important for people experiencing severe 
functional limitations in other aspects of life due to chronic breathlessness and their 
caregivers. For these patients, driving is associated with a sense of identity and feeling 

































































useful. Similar findings were reported by a previous qualitative study of three focus groups: i) 
low disability/broad life space, ii) high disability/broad life space, iii) high or low 
disability/constricted life space. Although all groups considered driving an important activity, 
the third group was the most affected by driving cessation which was perceived by them as 
devastating. [34] Importantly, the present study also shows that driving widens both patients’ 
and caregivers’ life space (i.e. the physical space in which they move and socially interact). 
[35,36] Previous evidence suggests that as patients become more restricted by chronic 
breathlessness, caregivers tend to adjust by slowing their life rhythm, also becoming more 
restricted. [37] Thus, it is likely that any strategies supporting patients’ function (such as 
driving) may also positively affect caregivers. [35] Functional decline is one of the major 
contributors to driving cessation in older age. [11] Older adults who stop driving have twice 
the risk of depressive symptoms compared to those who continue driving. [11] Importantly, 
there is a significant association between the well-being of these patients and their 
caregivers. [38]  Thus, risks and benefits for patients and caregivers need to be weighed 
carefully before advising patients not to drive. 
Most patients considered that their chronic breathlessness did not impact on their driving 
primarily because driving was sedentary and did not trigger breathlessness. Patients who 
had experienced or were experiencing breathlessness at rest explained that breathlessness 
affected their concentration when driving. Previous research has highlighted potential effects 
of uncontrolled symptoms on people’s driving skills. [39] Worsening breathlessness scores 
are associated with worsening performance in neuropsychological assessments but any 
relationship with driving performance is unknown. [40] Worsening breathlessness scores are 
associated with increased chances of experiencing breathlessness at rest. [23] Thus, it is 
possible that patients with worse breathlessness are particularly at risk of having some 
degree of psychomotor impairment that could affect driving. Interestingly, caregivers did not 
seem to notice any changes in patients’ ability to drive. This may result from patients’ 
adaptation to breathlessness, including development of driving strategies that are not 

































































evident to caregivers (e.g. increased attention, driving slightly slower). Reportedly, the use of 
oxygen while driving may be one of these strategies. Using oxygen while driving is legal in 
most countries but patients need to ensure oxygen tanks are adequately secured and 
respect specific state/country requirements. Given that driving cessation is also emotionally 
challenging for caregivers, caregivers may overlook changes in patients’ driving ability in 
order to keep them driving. [41]   
All participants agreed that their study drug/dose did not affect their perceived driving skills. 
Previous research had suggested that regular therapeutic opioid-agonists are unlikely to 
affect driving-related skills. [18] This study raises the hypothesis that low-doses of sustained-
release morphine may have no impact on driving even during therapy initiation and careful 
upward titration. This is in line with previous studies showing that uncontrolled symptoms are 
more likely to have an impact on driving than therapeutic opioids. [39] Despite that, both 
patients and caregivers were still concerned about potential side effects of sustained-release 
morphine that could affect their driving. Concerns about opioids are common amongst 
patients, caregivers and clinicians. [42,43] Interestingly, while patients’ concerns were 
focused on safety for themselves and others, caregi ers’ were more concerned with patients’ 
deterioration if they were to stop driving. Chronic breathlessness affects both patients and 
caregivers, involving both in symptom management and again reinforcing the patient-
caregiver unit as the unit of care. [44] 
This study suggests that initiating morphine for chronic breathlessness may raise concerns 
about driving for patients and caregivers, and those concerns need to be proactively 
addressed with both. Frequently, clinicians advise patients not to drive immediately after 
taking opioids. [45] There is a need for further research to understand if patients taking 
regular, low-dose, sustained-release morphine are able to drive safely given the different 
pharmacokinetic profile they have to immediate-release oral morphine solutions. [46] The 
relation between breathlessness and driving performance whist on opioids must also be 

































































explored as current legal morphine limits for driving (where imposed) are far higher than the 
doses used in this study. [13]
Strengths and Limitations
This is the first qualitative study reporting on people’s experiences of driving with chronic 
breathlessness and the perceived effects of regular, low-dose sustained-release morphine 
on driving ability. The inclusion of people taking different doses of morphine and placebo 
provided a range of different perspectives that could be compared and contrasted. The 
qualitative design limits generalisability, but findings point to important questions and future 
research directions, particularly in the context of growing concerns about drug-affected 
drivers. This study is limited by looking at self-reported effects on driving. People tend to 
overestimate their own driving performance. [47] Most studies conducted in this field asked 
participants to rate their driving ability compared with the “average driver”, rather than 
assessing aspects of their own driving. [48] The latter has been shown to more accurately 
reflect driving performance, and is closer to the approach used in this study. [48,49] 
Similarly, caregivers’ perception is not an optimal reflection of patients’ driving skills, but their 
assessment of specific driving aspects correlates with on-the-road performance. [50] Opioids 
may affect cognitive function, which may affect self-perception. [51] However, it is less likely 
that would be the case with small doses of morphine. [52]
A strength of this study is that participants were recruited from a phase III RCT that allowed 
COPD-status and morphine-dose transparency. While the participants may not be 
representative of the overall population with severe breathlessness associated with COPD, 
the RCT had a pragmatic design to ensure high external validity. [20,21] Due to the main trial 
dose-increment design, people were more likely to be taking morphine than placebo after the 
randomisation period (11:12 chance). This reduced the number of perspectives from people 

































































taking placebo, but increased the number of people who could provide useful information 
about morphine. 
What this study adds
This study highlights that driving is important for people living with chronic breathlessness 
and their caregivers. It also suggests that regular, low-dose, sustained-release morphine 
does not impact on patients’ perceived ability to drive. Based on these findings, there is a 
need to objectively evaluate the impact of chronic breathlessness on patients’ driving ability. 
Previous studies focused on objective measures of disease severity but not on the symptom 
itself. [53] It is also important to understand if people are safe to drive with low-doses of 
sustained-release morphine, particularly during therapy initiation and upward titration. 
Equally, the impact of uncontrolled symptoms such as chronic breathlessness on driving 
performance needs to be researched. There is a common assumption in the clinical setting 
that people should refrain from driving in the first hours or days after initiating any opioid. 
There are no published RCTs to confirm this should be the case with low-dose sustained-
release morphine. Due to lack of evidence to support decision-making, clinicians may advise 
people taking low dose sustained-release morphine to stop driving, but be aware that this 
may have severe implications for people’s well-being and social functioning.
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Table 1 - Patients Characteristics (n=13)




Oceanian (Australia or New Zealand) 11 
North-West European 2 
Usual language spoken at home
English 13 
Residence
Living in a private residence 13 
Marital status
Married or de facto 9 
Separated or divorced 2 
Widowed 2 
Highest level of education
Did not complete high school 4 
Completed high school 4
Completed a trade certificate 3
University Degree 2
mMRC score at baseline
3 13












IQR – Interquartile range; mMRC – modified Medical Research Council Scale; NRS – 
Numerical Rating Scale; AKPS – Australian Karnofsky Performance Status
































































Table 2 – Driving status for participants on trial (n=13)
Patient Gender Caregiver Driving status Reasons to stop driving
1 Female Husband Not currently driving Deemed unfit to drive 
2 Male Wife Active driver -
3 Male - Active driver -
4 Female Son Not currently driving Sold the car after husband died
5 Male Wife Not currently driving Deemed unfit to drive
6 Male Wife Active driver -
7 Female - Active driver -
8 Male Wife Active driver -
9 Male - Active driver -
10 Male - Not currently driving Sold the car due to financial issues
11 Male Wife Active driver -
12 Female Husband Active driver -
13 Male Wife Active driver (occasionally)
































































Table 3 – Maximum morphine doses patients took while on the BEAMS trial (n=13)
Doses of morphine on trial Cessation time-pointParticipant
Week 1 Week 2 Week 3 Extension
1 Placebo 8mg 16mg 16mg Completed the study
2 16 mg 16 mg 16 mg 16 mg Completed the study
3 Placebo Placebo 8 mg 8 mg Completed the study
4 Placebo Placebo Placebo - Withdrew after week 3
5 16mg 16mg 24mg 24mg Withdrew during extension
6 8 mg 16 mg 24 mg 24 mg Completed the study
7 16 mg 24 mg 32 mg - Withdrew after week 3
8 8 mg 8 mg 8 mg 8 mg Completed the study
9 Placebo 8 mg 8 mg 8 mg Withdrew during extension
10 8 mg 8 mg 8 mg 8 mg Completed the study
11 Placebo Placebo Placebo Placebo Withdrew during extension
12 8 mg 16 mg 24 mg 24 mg Completed the study
13 Placebo 8 mg 16 mg
End of random
isation stage
16 mg Completed the study
































































Table 4 - Comparative analysis of findings from patients and caregivers
Patients & Caregivers Patient Caregiver
1. Independence
Driving widens the “living-space” for 
both patient and caregiver
 Doing something
 Being useful
 Enjoyment and pleasure
 Fear of losing their ability to drive
 The most important activity 
 Happy to see patients enjoy themselves 
 More independence if the patient is able to 
drive
 Fear that patients lose their ability to drive 
2. Breathlessness impact on driving
Breathlessness does not impact on 
perceived driving
 Overall, breathlessness does not impact on 
driving
 Breathlessness at rest can affect concentration 
and the ability to drive
 Breathlessness does not affect the patients’ 
ability to drive safely 
 More confident about patients’ driving skills 
than the patients themselves
3. Driving while taking low-dose 
sustained-release morphine 
Sustained-release morphine does not 
impact on perceived driving 
 Did not perceive any changes in driving ability 
with the study drug
 Fears associated with low-dose morphine - 
putting others at risk
 Did not perceived any changes in patients’ 
driving ability with the study drug
 Fears associated with low-dose morphine – 
patients’ decline
Box 1 - Interview guide used for patients and caregivers
Questions asked to patients
1. How important is driving to you?
2. Before the study, was your breathlessness impacting your ability to drive? 
3. Were there any changes in your ability to drive after initiating the study medication?
Questions asked to caregivers
1. How important is it for you that [patient] is able to drive?
2. Before the study, was [patient’s] breathlessness impacting on his/her ability to drive?
3. Were there any changes in [patient’s] ability to drive after initiating the study medication?


































































Background: Chronic breathlessness is a disabling syndrome that profoundly impacts 
patients’ and caregivers’ lives. Driving is important for most people, including those with 
advanced disease. Regular, low dose, sustained-release morphine safely reduces 
breathlessness, but little is known about its impact on driving. 
Aim: To understand patients’ and caregivers’ (i) perspectives and experiences of driving with 
chronic breathlessness; and (ii) perceived impact of regular, low-dose, sustained-release 
morphine on driving.
Design: A qualitative study embedded in a pragmatic, phase III, randomised, placebo-
controlled trial (RCT) of low-dose, sustained-release morphine (≤32mg/24 hours) for chronic 
breathlessness. Semi-structured interviews were conducted immediately after participants 
withdrew or completed the RCT. Informed by grounded theory, a constant comparative 
approach to analysis was adopted. 
Setting/participants: Participants were recruited from an outpatients palliative-care service 
in Adelaide, Australia. Participants included: patients (n=13) with severe breathlessness 
associated with chronic obstructive pulmonary disease; and their caregivers (n=9).
Results: Participants were interviewed at home. Eleven received morphine 8-32mg. Three 
themes emerged: i) independence; ii) breathlessness’ impact on driving; and iii) driving while 
taking regular, low-dose, sustained-release morphine.  
Conclusions: Driving contributed to a sense of identity and independence. Being able to 
drive increased the physical and social space available to patients and caregivers, their 
social engagement and well-being. Patients reported breathlessness at rest may impair 
driving skills, while the introduction of sustained-release morphine seemed to have no self-
reported impact on driving. Investigating this last perception objectively, especially in terms 
of safety, is the subject of ongoing work. 
Keywords
Driving, opioids, morphine, breathlessness, dyspnea, caregivers, patients 

































































What is already known about the topic?
 Chronic breathlessness is a debilitating syndrome, which can be ameliorated by 
small doses of regular, low-dose, sustained-release morphine in some people.
 Driving is important for most adults, including the ones with life-limiting illnesses 
associated with chronic breathlessness.
 Despite growing concerns about the impact of opioids on driving ability, there are no 
studies investigating people’s experiences of driving with chronic breathlessness 
before or after initiating treatment with regular, low-dose, sustained-release 
morphine.  
What this paper adds?
 Being able to drive is important for people with chronic breathlessness and their 
caregivers because it provides them with a continuing sense of self-worth, 
independence, pleasure and widening life space.
 Episodes of intense breathlessness can impact on patients’ perceived ability to drive, 
which is not easily perceived by caregivers. 
 Although people have fears surrounding driving while taking morphine, regular, low-
dose sustained-release morphine does not seem to impact on patients’ self-
perceived driving ability.
Implications for practice, theory and policy
 In clinical practice, it is important to enquire about peoples’ perceived ability to drive 
with chronic breathlessness and the medications that they are prescribed.
 Clinical research should focus on investigating whether oral, low-dose sustained-
release morphine impacts on patients’ driving ability, particularly during initiating 
therapy and any subsequent dose increases. 
 Understanding the impact of low-dose, sustained release morphine on people’s 
driving ability is essential to inform guideline development about who is able to drive 
safely and who is not. 


































































Chronic breathlessness persists and is disabling despite optimal treatment of the underlying 
disease(s). [1] Chronic breathlessness affects almost 10% of adults and 17% of those ≥65 
years. [2] Patients with chronic obstructive pulmonary disease (COPD) are particularly 
affected, with >90% reporting breathlessness at some stage. [3] Chronic breathlessness is 
physically and psychologically debilitating, [4] leading to increasing dependence, social 
isolation, and worse health-related and mortality outcomes. [5, 6] Loss of independence is 
also profoundly distressing for caregivers, who struggle seeing their loved ones’ decline. [7, 
8] 
Driving provides a sense of freedom, independence, identity and hope. [9] Not driving 
worsens social isolation and is associated with worse health-related outcomes. [10, 11] One 
quarter of people with life-limiting illnesses continue driving. [12] Although there is ample 
evidence that chronic breathlessness severely restricts people’s everyday lives, the effect of 
chronic breathlessness on people’s driving ability has not been explored. 
Regular, low-dose (≤30mg/day), [13] sustained-release morphine safely reduces chronic 
breathlessness in people with COPD. [14, 15] Recently, low-dose, sustained-release 
morphine has been approved by regulatory bodies in Australia for the treatment of chronic 
breathlessness. [16] This is the first world approval of any medication for the symptomatic 
reduction of chronic breathlessness, likely increasing prescriptions for this indication. 
Simultaneously, there are concerns about safe driving while taking psychoactive substances, 
including prescribed opioids. [17] While high dose opioids can impair driving, it is unknown 
whether regular, low dose, sustained-release morphine impacts on patients’ ability to drive, 
particularly when initiating therapy and up-titration. [18] 
This aim of this qualitative study was to elicit patients’ and caregivers’ perceptions about 

































































driving with chronic breathlessness and to understand their perceptions about driving as 
regular, low dose, sustained release morphine was introduced. 
METHODS
Design
A qualitative study embedded in a pragmatic, phase III, randomised, placebo-controlled trial 
(RCT) evaluating the effectiveness of sustained-release morphine for people with chronic 
breathlessness and COPD (BEAMS trial). [19] The RCT had a parallel-arm, dose increment 
design. Participants were randomised to placebo, 8mg or 16mg of once-daily sustained-
release morphine for one week, with possible additional blinded up-titrations, of 8 or 16mg in 
weeks 2 and 3. Maximum daily doses of morphine by the end of the randomisation period 
ranged from 0mg (placebo) to 32mg (0, 8, 16, 24 or 32mg), with chances of being on 
placebo after randomisation being 1:12. The trial primary outcome measure was change in 
intensity of “worst breathlessness” in the previous 24 hours, measured with a 0-10 numerical 
rating scale after one week of therapy. The pragmatic design ensured that participants 
included in the RCT were a close reflection of the population of interest. [20,21] 
Setting and Participants
Participants were recruited from the metropolitan region serviced be the Southern Adelaide 
Palliative Services, Australia. Participants included: patients who had ceased their 
participation in the BEAMS trial [19] either by completion or withdrawal; and ‘the person 
closest to the patient’ (‘caregiver’), if present. [22] This sampling provided a broad range of 
perspectives. All patients had COPD and chronic breathlessness; a modified Medical 
Research Council (mMRC) breathlessness score of 3 or 4 corresponding to “stops for breath 
after walking about 100 meters or stops after a few minutes walking on the level” and “too 
breathlessness to leave the house or breathlessness when dressing or undressing”, 

































































respectively. [23,24] Participants were active drivers or people who had recently stopped 
driving and were still able to recall their experience of driving with severe chronic 
breathlessness. The latter group’s perceptions contributed to expand the understanding of 
the experience of driving with this disabling syndrome, but were not questioned about their 
experiences of driving after initiating sustained-release morphine.
Research Team
The interviewer (D.F.) has a medical background and was a full-time doctoral student with 
training in qualitative research. J.B. is Senior Clinical Lecturer and Honorary Consultant in 
Palliative Medicine with a medical and research background. A.H. is a university researcher 
with background in data collection and people-centred research. S.K. is a university 
researcher with a linguistics background. J.P. is a senior researcher with a background in 
palliative care nursing and qualitative research. D.C. is a researcher with expertise in chronic 
breathlessness.
Recruitment
Using convenience sampling, the trial nurses approached potential participants by 
telephone. If interested, they were then phoned by the interviewer (D.F.), with whom they 
had no previous contact. The interviewer explained the study’s objectives and scheduled a 
face-to-face meeting with potential participants to answer questions and obtain written 
consent. 
Data collection
Face-to-face, semi-structured interviews were conducted separately with patients and their 
caregivers at a location of their choice (July 2017- November 2018), providing participants 
with safe and private settings to express freely any concerns or emotions. [25,26] Interviews 
evaluated the overall impact of chronic breathlessness in people’s daily lives and perceived 

































































changes after initiating study drug. [19] Given the lack of evidence examining experiences of 
driving in people with chronic breathlessness, the interviews included three questions about 
driving, analysed in a separate sub-study (Box 1). 
Participants’ responses were recorded and transcribed verbatim (D.F.). Field notes were 
collected and the researcher kept a reflexive journal with impressions about each participant-
researcher interaction. Interview transcripts were not reviewed by participants to minimise 
burden on people already debilitated due to chronic breathlessness, given minimal 
advantages from doing this. [27] Potential misinterpretations were minimised by having a 
second researcher (A.H.) listen to interviews’ recordings, checking transcriptions for 
accuracy. Participants were only contacted again if there were disagreements between 
these researchers. Data were collected until saturation (i.e. no new concepts were 
emerging), as agreed between all researchers. 
Data Analysis
NVivo (V 11.4.0 for Mac) was used. The analysis was driven by the principles of grounded 
theory, using a constant comparative approach. [28,29,30] Given the lack of qualitative 
studies exploring people’s experiences of driving with chronic breathlessness, an inductive 
approach to analysis was adopted. [31] The constant comparative approach helped identify 
new concepts emerging from the data that could be explored in subsequent interviews. [30] 
Two researchers independently conducted open coding (D.F., A.H.) of all transcripts, which 
were grouped into themes (D.F.); each theme was illustrated with several quotes to confirm 
coding validity (D.F., J.B., S.K., J.P.). Patients’ and caregivers’ viewpoints were then 
compared and contrasted. 
Ethical considerations
The BEAMS trial was approved by relevant Human Research Ethics Committees 
(15/12/16/3.06) and was registered (NCT02720822). All participants provided written 
informed consent. 

































































The COREQ framework is used to report this study. [32]
RESULTS
Fifteen patients and 11 matched caregivers were invited to this study: two patients declined 
(so their caregivers were excluded); 13 patients and 9 caregivers were interviewed. 
Interviews took 20-55 minutes. Patients had a median age of 76 years (interquartile range 
[IQR] 68-78), nine of whom were men, living with their partners. All were still mobile outside 
their homes, but were severely restricted in their daily activities due to breathlessness (Table 
1).
Eight of 13 patients were regularly driving and one drove occasionally. Only two of nine men 
had stopped driving, while two of four women had stopped driving. The four participants who 
had stopped driving had all driven regularly until recently (Table 2). Eleven patients took 
sustained-release morphine during the study (Table 3): 8mg (n=4), 16mg (n=3), 24mg (n=3) 
and 32mg (n=1). 
Three major themes described the experience of driving for patients with chronic 
breathlessness and their caregivers: 1) independence, 2) breathlessness’ impact on driving, 
3) driving while taking regular low-dose sustained-release morphine (Table 4).
Theme 1 - Independence
Being able to drive helped patients keep their sense of self and feeling useful. This was 
more noticeable in patients experiencing severe functional limitations due to breathlessness. 
“Well, I suppose it’s something that I don’t do every day (driving) and you know, and I 
am doing something! Maybe that’s the reason why… Well I’ve always enjoyed driving 
actually but more so now, more so now, yeah… Probably because it’s something 
different in my life now, you know? I can do something! Whereas usually, I am just 
sitting.” [Patient 8]

































































Most patients reported that driving was one of the few activities that brought them a sense of 
joy and pleasure. Even those patients not required to drive (i.e. because their caregiver 
drove), still felt the need to drive at times for pure enjoyment.
“We have got the van and I drive the van. I love getting out in the country and 
driving.” [Patient 12]
For caregivers, seeing their partners enjoy themselves was particularly importantly. They 
acknowledged the role of driving in widening the physical space available to both the 
patients and themselves, a space that had been severely reduced by breathlessness in most 
cases. 
“Well, driving is important… There are certain things… When we go on holiday 
because he is not bothered about walking out on the streets, you know? (…) But we 
went to Barossa Valley last week, and I don’t know if you have been there, but we 
went to Mengler’s Hill to the look out. He got up there, well we drove up there of 
course, we got out of the car and we walked down a little bit to the picnic area there 
and he stayed there while I walked around and looked at it because walking down 
and up and down… [meaning it was tiresome for him]. So things like that you know?” 
[Caregiver 11]
For some patients, driving was their most important activity. One patient without a caregiver 
explained that driving was key to maintaining relationships and roles, whilst also providing a 
sense of purpose:
“I get my adult daughter every Saturday for a while, she is profoundly autistic, she 
just had her 26th birthday yesterday and it is very important to her. So I have got to 
drive to go get her, drive to bring her back. So it’s a very important thing, making sure 

































































I can still drive. (…) And that’s the main reason, apart from that, it is just to get to the 
shop and the doctor which are a kilometer away. That’s the only big one.” [Patient 3]
Another patient explained that driving was the only out-of-home activity he was still able to 
do independently and that losing it would be extremely disturbing.
“Well, I think the most important thing to be able to do at the moment is to be able to 
drive because physically there is nothing I can do, I can’t do anything”. [Patient 8]
 
Overall, people who were still driving expressed fear about not being able to drive in the 
future. Driving was seen as an important marker of independence and there was fear over 
any loss and its consequences. 
“I couldn’t give up driving, I couldn’t do that [disturbed facial expression]. I think it’s 
your independence, you know? And once that is taken away you’re reliant on 
somebody else…” [Patient 9]
For the four patients who had stopped driving, only one (male) reported that driving was 
important to maintain his independence. The other three patients (one male, two females) 
reported driving was not overly important because their caregivers could drive when needed. 
 
“It gives me a lot more freedom to have the car. I don’t do things that I would 
normally do… If I had the car and I felt like KFC for lunch, I can go and get it 
(laughing)… or if I wanted to go out for dinner with someone, I could just go and do it. 
Whereas now, for me to walk to the bus stop to get a bus somewhere, it’s just too 
hard…” [Patient 10]

































































“I don’t miss driving. B. (husband) does everything. We are together all the time 
anyway.” [Patient 1]
Breathlessness’ impact on driving
In general, patients and caregivers considered that breathlessness did not reduce patients’ 
driving skills because it did not require over-exertion. 
“Normally, I am fine. I don’t get tired driving.” [Patient 7]
Some patients reported they had situations in which they felt breathlessness at rest. When 
present, they felt their driving ability was affected. Strategies to overcome this limitation 
included not driving at all or using oxygen while driving. Interestingly, the use of oxygen in 
the car raised some concerns about its safety and legality.
“There were a couple of times in which I have been buggered a bit. I haven’t had the 
oxygen the night before, so I will put the oxygen on the car and I will have the oxygen 
running while I am driving. Whether that’s legal or not I don’t know.” [Patient 11]
One patient experiencing breathlessness at rest explained that breathlessness impacted on 
his concentration and hence ability to drive. When he drove, he felt anxious and concerned 
about his and other people’s safety.    
“For me it is not so much driving, but the concentration level about what is going on 
around. Stuff I used to take for granted, so I automatically did it before. Now, I have 
to make sure I do it. And it depends on the concentration because if it is 
concentrating on something that could end in a disaster, is a bit different to 
concentrating on something that might just a non-event anyway.” [Patient 13]

































































Overall, caregivers’ views matched patients’ views. Most caregivers confirmed that patients 
drove safely despite their breathlessness. For the only patient who stated that driving was 
stressful (previous quote, patient 13), the caregiver thought he could still drive safely. 
“Yes, usually when we go stay with our son at Wallaroo, he drives there. So he can. 
And he is quite good, I think. I don’t notice any diminishing of his driving skills. I feel 
quite relaxed when he is driving.” [Caregiver 13]
Driving while taking regular, low-dose sustained-release morphine
Participants’ views on driving were quite uniform, irrespectively of the drug (i.e. morphine or 
placebo) and dose. Most patients and caregivers perceived that the study drug did not have 
any perceived adverse impact on patients’ ability to drive, irrespectively of the study drug/dose. 
“No, no problems (to drive while taking the study drug).” [Patient 7 - maximum 
morphine dose 32mg]
 “No, no, not at all. I don’t think driving was affected (by morphine)”. [Caregiver 2 – 
maximum morphine dose 16mg]
Despite not perceiving any impact on driving with the study drug, a small number of 
participants were still concerned about the potential effects of morphine on driving. Most 
believed that the trial dose (up to 32mg sustained-release morphine a day) could impair 
driving. One caregiver did not want the patient to continue with morphine because she 
believed morphine could lead to driving cessation. One patient took action to minimise any 
negative impact of morphine on his driving skills. 

































































“I was concerned about… If he does take it, I think he wouldn’t be able to drive (…)  
and I don’t really want him to go on that because he loves driving and I think if he 
took it, that would be the end. I want him to be around for a few more years yet.” 
[Caregiver 8 – maximum morphine dose 8mg]
 “I have a friend coming here and he will sit with me (while I drive) and tells me what is 
going on with the driving. (…) I know they say if I am taking a quite powerful opioid 
drug that driving while under the immediate influence is probably not that smart. I would 




This is the first study reporting patients’ and caregivers’ perspectives and experiences of 
driving with chronic breathlessness. Additionally, the study was set in a study to compare 
before-and-after taking regular, low dose, oral sustained-release morphine. Findings suggest 
that driving is crucial in helping patients with chronic breathlessness keep a sense of identity, 
purpose, independence and connection to the outside world, while also being a source of joy 
and comfort for both patients and caregivers. According to patients, breathlessness at rest 
can reduce their driving skills but the study drug (i.e. morphine/placebo) had no perceived 
impact on their ability to drive.
Similar to healthy individuals, owning and driving a private vehicle is perceived as an 
amenity offering people freedom of movement. [33] However, participants’ reflections 
highlight that the ability to drive is particularly important for people experiencing severe 
functional limitations in other aspects of life due to chronic breathlessness and their 
caregivers. For these patients, driving is associated with a sense of identity and feeling 

































































useful. Similar findings were reported by a previous qualitative study of three focus groups: i) 
low disability/broad life space, ii) high disability/broad life space, iii) high or low 
disability/constricted life space. Although all groups considered driving an important activity, 
the third group was the most affected by driving cessation which was perceived by them as 
devastating. [34] Importantly, the present study also shows that driving widens both patients’ 
and caregivers’ life space (i.e. the physical space in which they move and socially interact). 
[35,36] Previous evidence suggests that as patients become more restricted by chronic 
breathlessness, caregivers tend to adjust by slowing their life rhythm, also becoming more 
restricted. [37] Thus, it is likely that any strategies supporting patients’ function (such as 
driving) may also positively affect caregivers. [35] Functional decline is one of the major 
contributors to driving cessation in older age. [11] Older adults who stop driving have twice 
the risk of depressive symptoms compared to those who continue driving. [11] Importantly, 
there is a significant association between the well-being of these patients and their 
caregivers. [38]  Thus, risks and benefits for patients and caregivers need to be weighed 
carefully before advising patients not to drive. 
Most patients considered that their chronic breathlessness did not impact on their driving 
primarily because driving was sedentary and did not trigger breathlessness. Patients who 
had experienced or were experiencing breathlessness at rest explained that breathlessness 
affected their concentration when driving. Previous research has highlighted potential effects 
of uncontrolled symptoms on people’s driving skills. [39] Worsening breathlessness scores 
are associated with worsening performance in neuropsychological assessments but any 
relationship with driving performance is unknown. [40] Worsening breathlessness scores are 
associated with increased chances of experiencing breathlessness at rest. [23] Thus, it is 
possible that patients with worse breathlessness are particularly at risk of having some 
degree of psychomotor impairment that could affect driving. Interestingly, caregivers did not 
seem to notice any changes in patients’ ability to drive. This may result from patients’ 
adaptation to breathlessness, including development of driving strategies that are not 

































































evident to caregivers (e.g. increased attention, driving slightly slower). Reportedly, the use of 
oxygen while driving may be one of these strategies. Using oxygen while driving is legal in 
most countries but patients need to ensure oxygen tanks are adequately secured and 
respect specific state/country requirements. Given that driving cessation is also emotionally 
challenging for caregivers, caregivers may overlook changes in patients’ driving ability in 
order to keep them driving. [41]   
All participants agreed that their study drug/dose did not affect their perceived driving skills. 
Previous research had suggested that regular therapeutic opioid-agonists are unlikely to 
affect driving-related skills. [18] This study raises the hypothesis that low-doses of sustained-
release morphine may have no impact on driving even during therapy initiation and careful 
upward titration. This is in line with previous studies showing that uncontrolled symptoms are 
more likely to have an impact on driving than therapeutic opioids. [39] Despite that, both 
patients and caregivers were still concerned about potential side effects of sustained-release 
morphine that could affect their driving. Concerns about opioids are common amongst 
patients, caregivers and clinicians. [42,43] Interestingly, while patients’ concerns were 
focused on safety for themselves and others, caregi ers’ were more concerned with patients’ 
deterioration if they were to stop driving. Chronic breathlessness affects both patients and 
caregivers, involving both in symptom management and again reinforcing the patient-
caregiver unit as the unit of care. [44] 
This study suggests that initiating morphine for chronic breathlessness may raise concerns 
about driving for patients and caregivers, and those concerns need to be proactively 
addressed with both. Frequently, clinicians advise patients not to drive immediately after 
taking opioids. [45] There is a need for further research to understand if patients taking 
regular, low-dose, sustained-release morphine are able to drive safely given the different 
pharmacokinetic profile they have to immediate-release oral morphine solutions. [46] The 
relation between breathlessness and driving performance whist on opioids must also be 

































































explored as current legal morphine limits for driving (where imposed) are far higher than the 
doses used in this study. [13]
Strengths and Limitations
This is the first qualitative study reporting on people’s experiences of driving with chronic 
breathlessness and the perceived effects of regular, low-dose sustained-release morphine 
on driving ability. The inclusion of people taking different doses of morphine and placebo 
provided a range of different perspectives that could be compared and contrasted. The 
qualitative design limits generalisability, but findings point to important questions and future 
research directions, particularly in the context of growing concerns about drug-affected 
drivers. This study is limited by looking at self-reported effects on driving. People tend to 
overestimate their own driving performance. [47] Most studies conducted in this field asked 
participants to rate their driving ability compared with the “average driver”, rather than 
assessing aspects of their own driving. [48] The latter has been shown to more accurately 
reflect driving performance, and is closer to the approach used in this study. [48,49] 
Similarly, caregivers’ perception is not an optimal reflection of patients’ driving skills, but their 
assessment of specific driving aspects correlates with on-the-road performance. [50] Opioids 
may affect cognitive function, which may affect self-perception. [51] However, it is less likely 
that would be the case with small doses of morphine. [52]
A strength of this study is that participants were recruited from a phase III RCT that allowed 
COPD-status and morphine-dose transparency. While the participants may not be 
representative of the overall population with severe breathlessness associated with COPD, 
the RCT had a pragmatic design to ensure high external validity. [20,21] Due to the main trial 
dose-increment design, people were more likely to be taking morphine than placebo after the 
randomisation period (11:12 chance). This reduced the number of perspectives from people 

































































taking placebo, but increased the number of people who could provide useful information 
about morphine. 
What this study adds
This study highlights that driving is important for people living with chronic breathlessness 
and their caregivers. It also suggests that regular, low-dose, sustained-release morphine 
does not impact on patients’ perceived ability to drive. Based on these findings, there is a 
need to objectively evaluate the impact of chronic breathlessness on patients’ driving ability. 
Previous studies focused on objective measures of disease severity but not on the symptom 
itself. [53] It is also important to understand if people are safe to drive with low-doses of 
sustained-release morphine, particularly during therapy initiation and upward titration. 
Equally, the impact of uncontrolled symptoms such as chronic breathlessness on driving 
performance needs to be researched. There is a common assumption in the clinical setting 
that people should refrain from driving in the first hours or days after initiating any opioid. 
There are no published RCTs to confirm this should be the case with low-dose sustained-
release morphine. Due to lack of evidence to support decision-making, clinicians may advise 
people taking low dose sustained-release morphine to stop driving, but be aware that this 
may have severe implications for people’s well-being and social functioning.
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